2026-08125Notice

FDA Extends Committee on Safe Pain Meds and Opioid Issues

Published Date: 4/27/2026

Notice

Summary

The FDA is renewing its Anesthetic and Analgesic Drug Products Advisory Committee for two more years, keeping it active until May 1, 2028. This committee helps make sure pain and anesthesia drugs are safe and effective, especially focusing on issues like opioid abuse. The renewal means the committee will keep advising the FDA without any new costs or changes to how it works right now.

No Economic Impacts Identified for this Document

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
4/27/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register